Abstract
Twenty-one clinical, biochemical, scan and tracerkinetic parameters were documented in 76 patients with Graves' disease who had received a standard 5-mCi therapy dose of 131I. Linear discriminant analysis was then undertaken to determine what combination of variables best predicted outcome. One year after therapy, 40 patients were euthyroid, 11 were hypothyroid, and 25 were still thyrotoxic. Linear discriminate functions combining 24-h 131I uptake, the presence or absence of thyroid eye signs and a computer-derived measurement of thyroid cell mass best discriminated the three outcome groups. The proportion of patients correctly reclassified according to outcome using these functions was, however, only just over 50%. It is concluded that no single or combination of pretreatment variables predicts early outcome with sufficient confidence to justify a rigorously ‘scientific’ approach to the administration of 131I therapy for Graves' disease.
Similar content being viewed by others
References
Armstrong DI, Rogers TGH, Brownlie BEW, Turner JG (1976) Thyroid vascularity and trapping function: Analysis of very early thyroidal technetium uptake. Int J Nucl Med Biol 3:65–70
Atkins HL (1978) Treatment of hyperthyroidism: Use of 131-I and 125-I. In: Spencer RP (ed) Therapy in nuclear medicine. Grune and Stratton, New York, pp 85–111
Blahd WH, Hays MT (1972) Graves' disease in the male. Arch Intern Med 129:33–40
Bliddal H, Molholm Hansen J, Rogowski P, Johansen K, Friis T, Siersbaek-Nielsen K (1982) Iodine-131 treatment of diffuse and nodular toxic goitre with or without antithyroid agents. Acta Endocrinol (Copenh) 99:517–521
Davies TF, Platzer M, Farid NR (1982) Prediction of therapeutic response to radioactive iodine in Graves' disease using TSH-receptor antibodies and HLA-status. Clin Endocrinol (oxf) 16:183–191
Dixon WJ (1981) BMDP statistical software. University of California Press, Berkeley
Green M, Wilson GM (1964) Thyrotoxicosis treated by surgery or iodine-131 with special reference to development of hypothyroidism. Br Med J 7:1005–1010
Sadler WA, Brownlie BEW (1975) Triiodothyronine radioimmunoassay in the assessment of thyroid function. NZ Med J 81:328–334
Solberg HE (1975) Discriminant analysis in clinical chemistry. Scand J Clin Lab Inves 35:705–712
Turner JG, Brownlie BEW, Rogers TGH (1976) Lithium as an adjunct to radioiodine therapy for thyrotoxicosis. Lancet 1:614–615
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Turner, J., Sadler, W., Brownlie, B. et al. Radioiodine therapy for Graves' disease: multivariate analysis of pretreatment parameters and early outcome. Eur J Nucl Med 11, 191–193 (1985). https://doi.org/10.1007/BF00279066
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00279066